Neil Redknap 🌎 πŸ³οΈβ€πŸŒˆ (@TravelWithNeil) header
Neil Redknap 🌎 πŸ³οΈβ€πŸŒˆ (@TravelWithNeil) profile picture

Retired teacher. Figure skating judge. Eurovision fan. Wordle sleuth. Gay introvert. N95 advocate. Still taking every covid precaution I did in 2020. #DavosSafe

Bowmanville, Ontario, Canada
Joined May 2015
Photo by Neil Redknap 🌎 πŸ³οΈβ€πŸŒˆ (@TravelWithNeil)Photo by Neil Redknap 🌎 πŸ³οΈβ€πŸŒˆ (@TravelWithNeil)Photo by Neil Redknap 🌎 πŸ³οΈβ€πŸŒˆ (@TravelWithNeil)Photo by Neil Redknap 🌎 πŸ³οΈβ€πŸŒˆ (@TravelWithNeil)Photo by Neil Redknap 🌎 πŸ³οΈβ€πŸŒˆ (@TravelWithNeil)Photo by Neil Redknap 🌎 πŸ³οΈβ€πŸŒˆ (@TravelWithNeil)Photo by Neil Redknap 🌎 πŸ³οΈβ€πŸŒˆ (@TravelWithNeil)Photo by Neil Redknap 🌎 πŸ³οΈβ€πŸŒˆ (@TravelWithNeil)Photo by Neil Redknap 🌎 πŸ³οΈβ€πŸŒˆ (@TravelWithNeil)Photo by Neil Redknap 🌎 πŸ³οΈβ€πŸŒˆ (@TravelWithNeil)
Neil Redknap 🌎 πŸ³οΈβ€πŸŒˆ retweeted
There's a subtle but crucial difference between lineages and subvariants. This season Novavax stuck with JN.1 lineage instead of LP.8.1 subvariant (which mRNA updated to). Why didn't they update? Because recent subvariants clustered antigenically with JN.1. They chose right.🧡
Replying to @michaelzlin
Novavax showed its JN.1 vax worked against LP.8.1, and said it wasn't clear if LP.8.1 would continue to dominate, so might be good to take a step back for better coverage. Indeed NB.1.8.1 is most prevalent now, which is closer to JN.1 than LP.8.1. Seems Novavax was correct.
3
65
3
347
12,201
Neil Redknap 🌎 πŸ³οΈβ€πŸŒˆ retweeted
Novavax showed its JN.1 vax worked against LP.8.1, and said it wasn't clear if LP.8.1 would continue to dominate, so might be good to take a step back for better coverage. Indeed NB.1.8.1 is most prevalent now, which is closer to JN.1 than LP.8.1. Seems Novavax was correct.
8
25
3
102
14,915
Neil Redknap 🌎 πŸ³οΈβ€πŸŒˆ retweeted
The risk of choosing the wrong strain as a vaccine's antigen is using a subvariant that fizzles out before a new vaccine is even put into place. By that point, antigenically distant strains could already be circulating. Choose a tree, not the leaves. nitter.cf/michaelzlin/status/196…
Replying to @michaelzlin
Novavax showed its JN.1 vax worked against LP.8.1, and said it wasn't clear if LP.8.1 would continue to dominate, so might be good to take a step back for better coverage. Indeed NB.1.8.1 is most prevalent now, which is closer to JN.1 than LP.8.1. Seems Novavax was correct.
2
3
20
868
Neil Redknap 🌎 πŸ³οΈβ€πŸŒˆ retweeted
Targeting JN.1, the current "tree trunk," potentially increases the breadth of crossprotection against emerging strains in light of the possibility that future dominant JN.1-descendant strains may not be descendants of KP subvariants. Learn more here: novavax.com/insights/value-t…
28
50
5
176
9,357
Neil Redknap 🌎 πŸ³οΈβ€πŸŒˆ retweeted
In 2020, the original Novavax formulation was able to protect against upper and lower respiratory tract infection in animals. Since then, more evidence has emerged supporting this finding. In human trials, Moderna reduced nasal viral load by 100x. Novavax decreased it by 600x.
Replying to @Daniel_E_Park
Novavax reduces viral load by 2.78 log10, while the Moderna vaccine was 2.12. The log10 scale is 10x for each step, indicating Moderna reduces viral load by just over 100x, and Novavax reduces viral load by over 600x. No significant reductions seen for others.
15
272
28
1,017
69,216
Neil Redknap 🌎 πŸ³οΈβ€πŸŒˆ retweeted
Novavax reduces viral load by 2.78 log10, while the Moderna vaccine was 2.12. The log10 scale is 10x for each step, indicating Moderna reduces viral load by just over 100x, and Novavax reduces viral load by over 600x. No significant reductions seen for others.
35
433
148
1,365
650,027
Neil Redknap 🌎 πŸ³οΈβ€πŸŒˆ retweeted
These results are in line with earlier animal models where the Novavax platform was associated with the largest decrease in viral replication in the upper respiratory tract. science.org/doi/10.1126/scii…
2
56
4
380
21,955
Neil Redknap 🌎 πŸ³οΈβ€πŸŒˆ retweeted
Yet another study that shows that Novavax-induced Abs clear virus from the upper respiratory tract better than RNA vax-induced Abs.
Vaccines likely lower transmission, in addition to reducing infection and severe illness. New study shows Novavax and Moderna significantly reduce viral load (amount of virus) in the upper respiratory tract. academic.oup.com/jid/advance…
24
223
22
1,022
78,087
Neil Redknap 🌎 πŸ³οΈβ€πŸŒˆ retweeted
One less known aspect of Novavax is that it's been shown to last at least a year in multiple studies. mRNA doesn't even come close to providing this level of protection.
Replying to @Daniel_E_Park
Further, duration is likely different across platforms. Although it's nearly impossible to evaluate duration with behavioral differences, variant shifts, etc., the Novavax platform has shown excellent durability up to 1 year in multiple studies nitter.cf/Daniel_E_Park/status/1…
11
137
7
662
25,015
Neil Redknap 🌎 πŸ³οΈβ€πŸŒˆ retweeted
If you shifted to Novavax (and you avoided exacerbating Long Covid) you made a good move for your health. The data on this drug are undeniable. βœ…Safety profile βœ… Effectiveness βœ… Durability
Excellent durability up to one year following Novavax booster doses shown in a new study from Japan. Correlates of protection estimate 66% throughout the first year following first booster, and 88% throughout second year after 2nd booster.
155
562
71
2,699
134,155
Neil Redknap 🌎 πŸ³οΈβ€πŸŒˆ retweeted
Once again, Novavax for the win πŸ† πŸ‘πŸ‘πŸ‘
If you shifted to Novavax (and you avoided exacerbating Long Covid) you made a good move for your health. The data on this drug are undeniable. βœ…Safety profile βœ… Effectiveness βœ… Durability
19
64
1
577
10,948
Neil Redknap 🌎 πŸ³οΈβ€πŸŒˆ retweeted
Additional findings from the PREVENT novavax randomized trial on the 4th sequential dose: - Robust and durable immune responses (8+ months) - Original strain vaccine had cross protection vs. strains circulating 3 years later (BA.5, BQ.1.1) - Low reactogenicity (side effects)
25
288
36
1,070
59,615
Neil Redknap 🌎 πŸ³οΈβ€πŸŒˆ retweeted
Even though COVID variants like BA.2 had acquired several years worth of mutations, the original Novavax formulation still provided a durable immune response 8 months after primary series. This sets it apart from mRNA both in terms of durability and breadth of protection.
Additional findings from the PREVENT novavax randomized trial on the 4th sequential dose: - Robust and durable immune responses (8+ months) - Original strain vaccine had cross protection vs. strains circulating 3 years later (BA.5, BQ.1.1) - Low reactogenicity (side effects)
4
67
9
292
8,428
Neil Redknap 🌎 πŸ³οΈβ€πŸŒˆ retweeted
I'll say what's increasingly clear: Novavax is the best choice for COVID-19 boosters. Lower side effects, less production of inactive/suppressive IgG4, broader coverage, and now better durability compared to RNA. Sometimes old school is the best school. nitter.cf/Daniel_E_Park/status/1…
Interesting: different immune responses to Novavax & mRNA COVID vaccines. TLDR: NVX has higher proportion of the "best" IgGs (IgG3), while mRNA have higher of the "not always good" IgG4. IMO more importantly, NVX has stronger Fc-effector functions journalofinfection.com/artic…
26
134
16
522
29,649
Neil Redknap 🌎 πŸ³οΈβ€πŸŒˆ retweeted
Replying to @michaelzlin
It's incredible that Novavax hasn't displaced the incumbents as the default vaccine. It's clearly superior.
15
39
6
272
7,055
Neil Redknap 🌎 πŸ³οΈβ€πŸŒˆ retweeted
Novavax reduces viral load by over 600x. If you have a choice, Novavax is the superior vaccine for everything that matters: effectiveness and safety.
Replying to @Daniel_E_Park
Novavax reduces viral load by 2.78 log10, while the Moderna vaccine was 2.12. The log10 scale is 10x for each step, indicating Moderna reduces viral load by just over 100x, and Novavax reduces viral load by over 600x. No significant reductions seen for others.
90
1,400
112
5,316
320,672
Neil Redknap 🌎 πŸ³οΈβ€πŸŒˆ retweeted
Novavax should be the default option for future vaccinations for Covid. Longer lasting immunity (65% at 1y), fewer side effects.
Just released: Pretty remarkable 1-year durability data for Novavax 2-dose primary series. Though there is some expected waning, there was >65% efficacy at 1y (mRNA options typically wane to this level by ~4-5 months). Also fewer waning differences by age. sciencedirect.com/science/ar…
240
692
80
2,776
233,946
Neil Redknap 🌎 πŸ³οΈβ€πŸŒˆ retweeted
The evidence in favour of Novavax just keeps piling up. Come on @GovCanHealth @JustinTrudeau Canadians deserve access to Novavax!
From a randomized trial, proof that the @Novavax booster induces less acute side effects and more sustained levels of anti-spike IgG antibodies than mRNA shots @moderna_tx @pfizer journalofinfection.com/artic… Right panel represents anti-spike IgG unadjusted fold reductions at baseline, 7, 28 and 84 days
6
74
7
262
7,155
Neil Redknap 🌎 πŸ³οΈβ€πŸŒˆ retweeted
πŸ‡¨πŸ‡¦ Novavax Availability Update πŸ“’ York Region Public Health Unit says that they are "currently exploring" procurement of the Novavax vaccine with the Ontario Ministry of health. Should the province arrive at an agreement with Novavax, systems are in place to order it.
Today from @yorkregiongovt PH re @novavax in Ontario: see attached. @twpiggott is this the same for your PH unit? @TOPublicHealth @flindall_steve @joeolivermd
31
122
30
542
38,898
Neil Redknap 🌎 πŸ³οΈβ€πŸŒˆ retweeted
Novavax Availability Update πŸ“’ It's now become clear that Public Health Units are a good pressure point to express demand for Novavax in Canada. There is unofficial chatter that Ontario may be negotiating for Novavax access. Keep contacting your PHUs about Novavax, Canadians!
She said no official word yet but behind the scenes things are looking good. So fingers crossed if you live in Ontario 🀞🏼
17
133
13
423
26,098